16 July 2018

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

16 July 2018 | n=91

  1. Musinguzi N, Muwonge T, Ngure K, Katabira E, et al.
    Comparison of SMS self-reported adherence with other adherence measures in a demonstration project of HIV pre-exposure prophylaxis in Kenya and Uganda.
    AIDS 2018.

  2. Liu Y, Blakely M, Sigel K, Thin TH, et al.
    Biomarker P16 predicts progression risk of anal low-grade squamous intraepithelial lesions.
    AIDS 2018.

  3. Harslof M, Knudsen AD, Benfield T, Nordestgaard BG, et al.
    No evidence of increased risk of thyroid dysfunction in well-treated people living with HIV.
    AIDS 2018.

  4. Gorry PR, Ahmad F, Mohl J, Alkhatib G, et al.
    Low levels of HIV-1 envelope-mediated fusion are associated with long-term survival of an infected CCR5-/- patient.
    AIDS 2018.

  5. Kelly H, Chikandiwa A, Warman R, Segondy M, et al.
    Associations of human gene EPB41L3 DNA methylation and cervical intraepithelial neoplasia in women living with HIV-1 in Africa.
    AIDS 2018.

  6. Duarte HA, Beck IA, Levine M, Kiptinness C, et al.
    Implementation of a point mutation assay for HIV drug resistance testing in Kenya: performance, challenges, and cost.
    AIDS 2018.

  7. Koss CA, Liu AY, Castillo-Mancilla J, Bacchetti P, et al.
    Similar tenofovir hair concentrations in men and women after directly-observed: dosing of TDF/FTC: implications for PrEP adherence monitoring.
    AIDS 2018.

  8. Lee H, Wu XK, Genberg BL, Mugavero MJ, et al.
    Beyond binary retention in HIV care: Predictors of the dynamic processes of patient engagement, disengagement, and re-entry into care in a US clinical cohort.
    AIDS 2018.

  9. Chang CC, Naranbhai V, Stern J, Roche M, et al.
    Variation in cell associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator BMAL-1.
    AIDS 2018.

  10. Ortega PAS, Saulle I, Mercurio V, Ibba SV, et al.
    The interleukin 21 (IL 21)/ microRNA-29 (miR-29) axis is associated with natural resistance to HIV-1 infection.
    AIDS 2018.

  11. Noret M, Balavoine S, Noret M, Pintado C, et al.
    Daily or on demand oral TDF/FTC for HIV pre-exposure prophylaxis: experience from an hospital-based clinic in France.
    AIDS 2018.

  12. Worodria W, Ssempijja V, Hanrahan C, Ssegonja R, et al.
    Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ counts.
    AIDS 2018.

  13. Msukwa MT, Estill J, Haas AD, van Oosterhout JJ, et al.
    Weight gain of HIV-exposed, uninfected children born before and after introduction of the "Option B+" programme in Malawi.
    AIDS 2018.

  14. Hunter MD, Shenoy A, Dwork A, Elkind MSV, et al.
    Brain vascular intima vulnerability among HIV-positive and negative individuals.
    AIDS 2018.

  15. Lahiri CD, Brown NL, Ryan KJ, Acosta EP, et al.
    HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.
    AIDS 2018.

  16. Matson TE, Mcginnis KA, Rubinsky AD, Frost MC, et al.
    Gender and alcohol use: influences on HIV care continuum in a national cohort of patients with HIV.
    AIDS 2018.

  17. Clifford GM, Siproudhis L, Piroth L, Poizot-Martin I, et al.
    Determinants of high-grade anal intraepithelial lesions in HIV-positive men having sex with men.
    AIDS 2018.

  18. Golob JL, Stern J, Holte S, Kitahata MM, et al.
    HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients.
    AIDS 2018.

  19. Ulfhammer G, Eden A, Mellgren A, Fuchs D, et al.
    Persistent CNS immune activation following > 10 years of effective HIV antiretroviral treatment.
    AIDS 2018.

  20. Adzhubei AA, Anashkina AA, Tkachev YV, Kravatsky YV, et al.
    Modelling interaction between HIV-1 Nef and calnexin.
    AIDS 2018.

  21. Ficht AL, Komba A, Bisimba J, Mlanga E, et al.
    The time is now: closing the pediatric treatment gap and building resilience among female sex workers and their children.
    AIDS 2018.

  22. Rossotti R, Maggioni M, Merli M, Orcese C, et al.
    Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
    AIDS 2018;32:1727-1729.

  23. Vermund SH, Kelley KF.
    Impact of HIV on human papilloma virus-mediated cervical disease progression.
    AIDS 2018;32:1715-1717.

  24. Heffron R, Mugo N, Hong T, Celum C, et al.
    Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.
    AIDS 2018;32:1707-1713.

  25. Masaba R, Borkowf CB, Girde S, Zeh C, et al.
    Adverse fetal and infant outcomes among HIV-infected women who received either nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based antiretroviral therapy for prevention of mother-to-child transmission.
    AIDS 2018;32:1625-1632.

  26. van der Velden Y, Villaudy J, Siteur-van Rijnstra E, van der Linden C, et al.
    Protective efficacy of broadly neutralizing antibody PGDM1400 against HIV-1 challenge in humanized mice.
    AIDS Res Hum Retroviruses 2018.

  27. Sun J, Zhu B, Feng Y, Xie Y, et al.
    Near Full-Length Genome Sequence of a Novel HIV-1 Recombinant Form (CRF01_AE/07_BC) Detected Among Men Who Have Sex with Men in Zhejiang, China.
    AIDS Res Hum Retroviruses 2018.

  28. Sugawara S, Thomas D, Balagopal A.
    HIV-1 Infection and Type 1 Interferon: Navigating through Uncertain Waters.
    AIDS Res Hum Retroviruses 2018.

  29. Lu X, Chen S, Zhao H, Li Y, et al.
    Baseline investigation of HIV-1 primary drug resistance among newly diagnosed treatment-naive HIV-1 individuals in Hebei, China.
    AIDS Res Hum Retroviruses 2018.

  30. Nance R, Crane H, Ritchings C, Rosenblatt LC, et al.
    Differentiation of Type 1 and Type 2 Myocardial Infarctions among HIV-infected patients requires adjudication due to overlap in risk factors.
    AIDS Res Hum Retroviruses 2018.

  31. Zhou JO, Ton T, Morriss JW, Nguyen D, et al.
    Structural Insights from HIV-Antibody Co-Evolution and Related Immunization Studies.
    AIDS Res Hum Retroviruses 2018.

  32. Safeek RH, Hall KS, Lobelo F, Del Rio C, et al.
    Low Physical Activity among Persons Living with HIV/AIDS is Associated with Poor Physical Function.
    AIDS Res Hum Retroviruses 2018.

  33. Manfio VM, Ingrid Tasca K, Gatto M, da Silva VL, et al.
    HIV-Infected Pregnant Women: A Microbial Translocation and Inflammatory Status Discussion.
    AIDS Res Hum Retroviruses 2018.

  34. McClymont E, Lee M, Raboud J, Coutlee F, et al.
    The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living with HIV.
    Clin Infect Dis 2018.

  35. de Voux A, Bernstein K, Bradley H, Kirkcaldy RD, et al.
    Syphilis testing among sexually active men who have sex with men and who are receiving medical care for HIV in the United States-Medical Monitoring Project, 2013-2014.
    Clin Infect Dis 2018.

  36. Muncunill J, Baptista MJ, Hernandez-Rodriguez A, Dalmau J, et al.
    Plasma EBV-load as an early biomarker and prognostic factor of HIV-related lymphomas.
    Clin Infect Dis 2018.

  37. Siegler AJ, Mayer KH, Liu AY, Patel RR, et al.
    Developing and assessing the feasibility of a home-based PrEP monitoring and support program.
    Clin Infect Dis 2018.

  38. Abbasi J.
    Anthony Fauci, MD: Working to End HIV/AIDS.
    JAMA 2018.

  39. Moucheraud C, Chasweka D, Nyirenda M, Schooley A, et al.
    A Simple Screening Tool May Help Identify High-Risk Children for Targeted HIV Testing in Malawian Inpatient Wards.
    J Acquir Immune Defic Syndr 2018.

  40. Chow FC, Wang H, Li Y, Mehta N, et al.
    Cerebral Vasoreactivity Evaluated by the Breath Holding Challenge Correlates with Performance on A Cognitive Screening Test in Persons Living with Treated HIV Infection in China.
    J Acquir Immune Defic Syndr 2018.

  41. Chen M, Yen YF, Lan YC, Jen IA, et al.
    Risk of Diffuse Infiltrative Lymphocytosis Syndrome in HIV-Infected Patients: A Nationwide Population-Based Cohort Study.
    J Acquir Immune Defic Syndr 2018.

  42. Mark D, Geng E, Vorkoper S, Essajee S, et al.
    Making Implementation Science Work for Children and Adolescents Living With HIV.
    J Acquir Immune Defic Syndr 2018;78 S:S58-S62.

  43. Ciaranello A, Sohn AH, Collins IJ, Rothery C, et al.
    Simulation Modeling and Metamodeling to Inform National and International HIV Policies for Children and Adolescents.
    J Acquir Immune Defic Syndr 2018;78 S:S49-S57.

  44. Ford D, Turner R, Turkova A, Penazzato M, et al.
    Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.
    J Acquir Immune Defic Syndr 2018;78 S:S40-S48.

  45. Abrams EJ, Ananworanich J, Archary M, Ngongondo M, et al.
    Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration.
    J Acquir Immune Defic Syndr 2018;78 S:S32-S39.

  46. Oliveras C, Cluver L, Bernays S, Armstrong A, et al.
    Nothing About Us Without RIGHTS-Meaningful Engagement of Children and Youth: From Research Prioritization to Clinical Trials, Implementation Science, and Policy.
    J Acquir Immune Defic Syndr 2018;78 S:S27-S31.

  47. Sohn AH, Judd A, Mofenson L, Vicari M, et al.
    Using Observational Data to Inform HIV Policy Change for Children and Youth.
    J Acquir Immune Defic Syndr 2018;78 S:S22-S26.

  48. Armstrong A, Nagata JM, Vicari M, Irvine C, et al.
    A Global Research Agenda for Adolescents Living With HIV.
    J Acquir Immune Defic Syndr 2018;78 S:S16-S21.

  49. Penazzato M, Irvine C, Vicari M, Essajee SM, et al.
    A Global Research Agenda for Pediatric HIV.
    J Acquir Immune Defic Syndr 2018;78 S:S10-S15.

  50. Irvine C, Armstrong A, Nagata JM, Rollins N, et al.
    Setting Global Research Priorities in Pediatric and Adolescent HIV Using the Child Health and Nutrition Research Initiative (CHNRI) Methodology.
    J Acquir Immune Defic Syndr 2018;78 S:S3-S9.

  51. Bekker LG, Siberry GK, Hirnschall G.
    Ensuring Children and Adolescents Are Not Left Behind.
    J Acquir Immune Defic Syndr 2018;78 S:S1-S2.

  52. Kaliel D, McCarthy E, Tayag J, Berry A, et al.
    Sustainability and Accelerating Children's HIV/AIDS Treatment (ACT) Initiative: Lessons for the Next Treatment Surge.
    J Acquir Immune Defic Syndr 2018;78 S:S142-S146.

  53. Saito S, Chung H, Mahy M, Radin AK, et al.
    Pediatric HIV Treatment Gaps in 7 East and Southern African Countries: Examination of Modeled, Survey, and Routine Program Data.
    J Acquir Immune Defic Syndr 2018;78 S:S134-S141.

  54. Penazzato M, Sugandhi N, Essajee S, Doherty M, et al.
    Getting Treatment and Care Services Right for Children and Adolescents to Reach High Viral Suppression.
    J Acquir Immune Defic Syndr 2018;78 S:S128-S133.

  55. Grimsrud A, Bygrave H, Wilkinson L.
    For Family-Centered Differentiated Service Delivery for HIV.
    J Acquir Immune Defic Syndr 2018;78 S:S124-S127.

  56. Willis N, Napei T, Armstrong A, Jackson H, et al.
    Zvandiri-Bringing a Differentiated Service Delivery Program to Scale for Children, Adolescents, and Young People in Zimbabwe.
    J Acquir Immune Defic Syndr 2018;78 S:S115-S123.

  57. Modi S, Broyles LN, Montandon M, Itoh M, et al.
    Beyond Early Infant Diagnosis: Changing the Approach to HIV-Exposed Infants.
    J Acquir Immune Defic Syndr 2018;78 S:S107-S114.

  58. Medley AM, Hrapcak S, Golin RA, Dziuban EJ, et al.
    Strategies for Identifying and Linking HIV-Infected Infants, Children, and Adolescents to HIV Treatment Services in Resource Limited Settings.
    J Acquir Immune Defic Syndr 2018;78 S:S98-S106.

  59. Simon KR, Flick RJ, Kim MH, Sabelli RA, et al.
    Family Testing: An Index Case Finding Strategy to Close the Gaps in Pediatric HIV Diagnosis.
    J Acquir Immune Defic Syndr 2018;78 S:S88-S97.

  60. Amzel A, Srivastava M, Isavwa A, Sanders J, et al.
    Community-Based Interventions to Reach 95-95-95 for Children and Adolescents: An Exploratory Programmatic Review From Lesotho.
    J Acquir Immune Defic Syndr 2018;78 S:S81-S87.

  61. Kim MH, Wanless RS, Caviness AC, Golin R, et al.
    Multimonth Prescription of Antiretroviral Therapy Among Children and Adolescents: Experiences From the Baylor International Pediatric AIDS Initiative in 6 African Countries.
    J Acquir Immune Defic Syndr 2018;78 S:S71-S80.

  62. Harrison K, Robinson J, Marks L, Blander J, et al.
    ACTing in Partnership to Accelerate Impact.
    J Acquir Immune Defic Syndr 2018;78 S:S65-S70.

  63. Siberry GK, Amzel A, Watts DH, Ahmed S, et al.
    Supplement Introduction: Accelerating Children's HIV/AIDS Treatment (ACT) Initiative: Using What We Learned to Maintain the Pace to Close the Pediatric HIV Treatment Gap.
    J Acquir Immune Defic Syndr 2018;78 S:S63-S64.

  64. MacDonald DM, Melzer AC, Collins G, Avihingsanon A, et al.
    Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the Start Pulmonary Substudy.
    J Acquir Immune Defic Syndr 2018.

  65. Chang E, Mapakshi SR, Mbang P, El-Mallawany NK, et al.
    The impact of protease inhibitors on HIV-associated Kaposi sarcoma incidence: a systematic review.
    J Acquir Immune Defic Syndr 2018.

  66. Behrends CN, Nugent AV, Des Jarlais DC, Frimpong JA, et al.
    Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States.
    J Acquir Immune Defic Syndr 2018.

  67. Zhang Y, Sivay MV, Hudelson SE, Clarke W, et al.
    Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068.
    J Acquir Immune Defic Syndr 2018.

  68. Knudsen AD, Gelpi M, Afzal S, Ronit A, et al.
    Prevalence of Peripheral Artery Disease is Higher in Persons Living with HIV Compared to Uninfected Controls.
    J Acquir Immune Defic Syndr 2018.

  69. Apondi E, Humphrey JM, Sang E, Mwangi A, et al.
    Trends Over Time for Adolescents Enrolling in HIV Care in Kenya, Tanzania, and Uganda from 2001-2014.
    J Acquir Immune Defic Syndr 2018.

  70. Caucheteux S, Piguet V.
    Vaginal epidermal dendritic cells: defense against HIV-1 or a safe haven?
    J Clin Invest 2018.

  71. Lopez-Cortes LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, et al.
    Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
    J Infect Dis 2018.

  72. Gebremicael G, Kassa D, Quinten E, Alemayehu Y, et al.
    Host gene expression kinetics during treatment of tuberculosis in HIV-coinfected individuals is independent of HAART therapy.
    J Infect Dis 2018.

  73. Ning T, Nie J, Huang W, Li C, et al.
    Antigenic Drift of H7N9 Viral Hemagglutinin.
    J Infect Dis 2018.

  74. Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, et al.
    Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1.
    J Infect Dis 2018.

  75. Fulcher JA, Hussain SK, Cook R, Li F, et al.
    Effects of Substance Use and Sex Practices on the Intestinal Microbiome During HIV-1 Infection.
    J Infect Dis 2018.

  76. Jose S, Hamzah L, Jones R, Williams D, et al.
    Chronic Kidney Disease Risk in African and Caribbean Populations with HIV.
    J Infect Dis 2018.

  77. Jogeda EL, Avi R, Pauskar M, Kallas E, et al.
    Association of IFNlambda4 rs12979860 Polymorphism with the Acquisition of HCV and HIV Infections among People Who Inject Drugs.
    J Med Virol 2018.

  78. Song JE, Ahn MY, Kim WJ, Kim SW, et al.
    Prevalence of CCR5 tropism among HIV-1-infected patients in South Korea.
    J Med Virol 2018.

  79. Mavigner M, Habib J, Deleage C, Rosen E, et al.
    SIV persistence in cellular and anatomic reservoirs in ART-suppressed infant rhesus macaques.
    J Virol 2018.

  80. Chan KW, Pan R, Costa M, Gorny MK, et al.
    Structural Comparison of Human Anti-HIV-1 gp120 V3 MAbs of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    J Virol 2018.

  81. Buffone C, Martinez-Lopez A, Fricke T, Opp S, et al.
    Nup153 Unlocks the Nuclear Pore Complex for HIV-1 Nuclear Translocation in Non-dividing Cells.
    J Virol 2018.

  82. Ojwach DBA, MacMillan D, Reddy T, Novitsky V, et al.
    Pol-driven replicative capacity impacts disease progression in HIV-1 subtype C infection.
    J Virol 2018.

  83. Schwartz JA, Zhang H, Ende Z, Deymier MJ, et al.
    Characterization of the plasmacytoid dendritic cell response to transmitted/founder and non-transmitted variants of HIV-1.
    J Virol 2018.

  84. Chien H, Alston CI, Dix RD.
    Suppressor of Cytokine Signaling (SOCS)1 and SOCS3 Are Stimulated Within the Eye During Experimental Murine Cytomegalovirus Retinitis in Mice With Retrovirus-Induced Immunosuppression.
    J Virol 2018.

  85. Khan SN, Sok D, Tran K, Movsesyan A, et al.
    Targeting the HIV-1 spike and co-receptor with bi- and trispecific antibodies for single-component broad inhibition of entry.
    J Virol 2018.

  86. Hovanessian AG, Soundaramourty C, Benferhat R, Le Grand R, et al.
    Vaccination with the conserved caveolin-1 binding motif in HIV-1 glycoprotein gp41 delays the onset of viral infection and provides partial protection in SHIV-challenged cynomolgus macaques.
    J Virol 2018.

  87. Noto A, Procopio FA, Banga R, Suffiotti M, et al.
    CD32(+) and PD-1(+) Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals.
    J Virol 2018.

  88. Heusinger E, Deppe K, Sette P, Krapp C, et al.
    Preadaptation of SIVsmm facilitated Env-mediated counteraction of human tetherin by HIV-2.
    J Virol 2018.

  89. Yan Q, Zhao R, Shen C, Wang F, et al.
    Upregulation of miR-711 mediates HIV-1 Vpr promotion of KSHV latency and induction of pro-proliferative/survival cytokines by targeting the Notch/NF-kappaB signaling axis.
    J Virol 2018.

  90. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, et al.
    Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
    N Engl J Med 2018;379:138-149.

  91. Mbuthia JK, Kabera BM, Karuga R, Ivui G, et al.
    A Cross-sectional Study to Compare Hepatitis B Immunity in HIV-infected and HIV-uninfected Kenyan Children After Primary Hepatitis B Immunization.
    Pediatr Infect Dis J 2018;37:e214-e215.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

16 July 2018

09 July 2018

02 July 2018

25 June 2018

18 June 2018

16 July 2018

Multidisciplinary Journal Club

  1. Moussata D, Allez M, Cazals-Hatem D, Treton X, et al.
    Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
    Gut. 2018;67:616-624.

  2. Wang A, Gaca JG, Chu VH.
    Management Considerations in Infective Endocarditis: A Review.
    JAMA. 2018;320:72-83.

  3. Anand IS, Gupta P.
    Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies.
    Circulation. 2018;138:80-98.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016